Kymera Therapeutics, Inc. (KYMR)
86.14
-2.86
(-3.21%)
USD |
NASDAQ |
Apr 16, 16:00
86.17
+0.03
(+0.03%)
After-Hours: 20:00
Kymera Therapeutics Cash from Investing (Quarterly) : -394.40M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -1.835B |
| Revolution Medicines, Inc. | 74.88M |
| Regeneron Pharmaceuticals, Inc. | 220.30M |
| Structure Therapeutics, Inc. | 56.31M |
| ACADIA Pharmaceuticals, Inc. | -55.87M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -66.75M |
| Cash from Financing (Quarterly) | 705.22M |
| Free Cash Flow | -234.34M |
| Free Cash Flow Per Share (Quarterly) | -0.7435 |
| Free Cash Flow to Equity (Quarterly) | -65.11M |
| Free Cash Flow to Firm (Quarterly) | -66.76M |
| Free Cash Flow Yield | -3.22% |